All stock reports

JAGSNPHARM evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-14T13:56:22.473308+00:00

Metrics

latest_annual_period
2026-03-31
revenue
2872250000.0
net_income
430820000.0
operating_cash_flow
468120000.0
free_cash_flow
466640000.0
total_assets
3166770000.0
total_liabilities
405050000.0
total_equity
2761720000.0
cash
100420000.0
total_debt
81650000.0
revenue_growth
0.0688794117209246
earnings_growth
-0.22179873918462456
net_margin
0.14999390721559752
roe
0.15599698738467332
debt_to_equity
0.029564908824935187
cash_conversion
1.0865790817510794
free_cash_flow_margin
0.16246496648968578
trailing_pe
35.47
forward_pe
Not supplied
peg_ratio
Not supplied
price_to_book
Not supplied
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Trend Continuation Pullback

Research only. Direction: LONG.

Tests continuation after a controlled retracement within an established trend

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
Price breach below slow EMA
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-e46da3dad73d231c11c634d290f70dabd31a52f77388a05ee777e77418a04df7
Policy
stock-decisions-v1
Evidence bundle hash
ee6caaea18788e9d8340ff0dbdf629a6378bab222107afeebad4fc402ca47ab9
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: dcfb93e9f91ac4a092129cdffed037c6f854c75831db77957dfce1dad233e9cd
  • daily-price: 0aa5059135f686d2fac8c475503810c7cab76f3db0fe234725825c6d6b603a24
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: VERIFIED. The cached closing price on 2026-10-01 was INR 231.73. The trailing 5-session price return was -6.18%. The trailing 20-session price return was -0.74%. The trailing 60-session price return was 2.97%. The trailing 250-session price return was 9.58%.

Risks

Average cached traded value over twenty sessions was INR 144,670,202. The closing price was -6.18% below its highest close in the available trailing year.

Follow Up

The cached financial metric latest annual period is 2026-03-31. The cached financial metric revenue growth is 0.0688794117209246. The cached financial metric net margin is 0.14999390721559752. The cached financial metric roe is 0.15599698738467332. The cached financial metric debt to equity is 0.029564908824935187. The cached financial metric cash conversion is 1.0865790817510794.

Cached observations and evidence limits